Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339 is registered in ClinicalTrials.gov with Nanobiotix as lead sponsor.

NCT NCT03589339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03589339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Lead sponsor
Nanobiotix
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 16, 2019
Completion date
August 30, 2027
Enrollment
145 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, metastasis from malignant melanoma of skin (disorder), metastasis from malignant tumor of bladder (disorder), metastasis from malignant tumor of cervix, metastasis from malignant tumor of liver, metastatic nsclc, metastatic renal cell carcinoma, metastatic triple-negative breast carcinoma, microsatellite instability-high solid malignant tumour, radiotherapy, squamous cell carcinoma of head and neck